In the RASCAL study, which was designed to assess the effect of the phenotypic expression of the KRAS mutation subtypes, only one specific mutation in codon 12 (glycine-to-valine replacement, present in 9% of the colorectal tumors) was associated with poor outcomes (30% increase in relapse and death). This evidence concerns the gene KRAS and colorectal neoplasm.